Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492838 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL29354999 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL16081269 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL2461163 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL12264514 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL19807522 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3950346 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL472609 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL9498481 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL4803030 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845814-A | Application of N6-cyclopentyl adenosine, derivatives and salts thereof in treating liver diseases | 上海中医药大学 | 2024-10-29 | — | — | CN | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| WO-2021003393-A1 | METHOD, COMPOSITION, AND APPARATUS FOR TREATING HEADACHE | Equinox Ophthalmic, Inc. (US) | 2021-01-07 | — | — | WO | claimed |
| CN-111789950-A | Method and pharmaceutical composition for regulating fear memory consolidation | 浙江大学 | 2020-10-20 | — | — | CN | claimed |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | claimed |
| CN-110169976-A | Medicine composition for treating depression and its application containing adenosine a1 receptor agonists | 北京大学 | 2019-08-27 | — | — | CN | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| WO-2017137528-A1 | ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2017-08-17 | — | — | WO | claimed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-1683509-A1 | METHOD AND COMPOSITION FOR HAIR THICKENING | SHISEIDO COMPANY, LTD. (JP) | 2006-07-26 | — | — | EP | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| US-6955814-B1 | protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention by administering potassium channel opener or agonist and adenosine receptor agonist and local anesthetic | GLOBAL CARDIAC SOLUTIONS PTY LTD. (AU) | 2005-10-18 | — | — | US | claimed |
| US-20050171050-A1 | Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine | GLOBAL CARDIAC SOLUTIONS PTD. LTD. (AU) | 2005-08-04 | — | — | US | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20040146474-A1 | Method for softening lines and relaxing the skin with adenosine and adenosine analogues | L'OREAL (FR) | 2004-07-29 | — | — | US | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| EP-1424064-A1 | Use of adenosin or an adenosin analog to smooth out fine lines | L'OREAL (FR) | 2004-06-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | ADORA3 7/4885ADORA2A 4/4885ADORA1 2/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA2A 10/4885ADORA1 39/4885 |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | ADORA3 13/4885ADORA2A 8/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.